EDITORIALS
Resynchronisation therapy in heart failure: searching for predictors
Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
Correspondence to:
William T Abraham, MD, The Ohio State University Heart Center, 473 West 12th Avenue, Room 110P DHLRI, Columbus, OH 43210-1252, USA; William.Abraham@osumc.edu
| The first 150 words of the full text of this article appear below. |
Cardiac resynchronisation therapy (CRT) has been gaining clinical application. However, prospective identification of responders or non-responders to this therapy is still challenging.
Over the past decade, significant progress has been made in understanding the deleterious effects of ventricular dysynchrony in patients with congestive heart failure (CHF). Randomised controlled clinical trials have demonstrated that CRT improves clinical symptoms and left ventricular (LV) function, and reduces morbidity and mortality in patients with moderate to severe CHF (New York Heart Association Functional Class III-IV).1–4 However, up to one-third of patients may not respond fully to CRT.
Synchrony of heart contraction is important because it is effective and energetically efficient. Left bundle branch block, a common form of "electrophysiological abnormality" in heart failure, can result in three mechanical problems: 1) abnormal left atrioventricular timing, 2) delayed intraventricular timing, and 3) delayed interventricular timing. The net result is a decline in systolic function with reduced
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Relevant Article
- Instantaneous effects of resynchronisation therapy on exercise performance in heart failure patients: the mechanistic role and predictive power of total isovolumic time
- T V Salukhe, K Dimopoulos, R Sutton, P Poole-Wilson, M Y Henein, M Morgan, J R Clague, and D P Francis
Heart 2008 94: 59-64.[Abstract] [Full Text] [PDF]
This article has been cited by other articles:
-
Poulter, N. R.
(2008). Selecting a fixed combination to improve morbidity/mortality: the weight of evidence with ASCOT. Eur Heart J Suppl
10: G21-G28
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Dilated cardiomyopathy
-
Drugs: cardiovascular system
-
Echocardiography
-
Heart failure
-
Hypertension
- Relevant Article
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
